vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and ONE Group Hospitality, Inc. (STKS). Click either name above to swap in a different company.
ONE Group Hospitality, Inc. is the larger business by last-quarter revenue ($207.0M vs $177.4M, roughly 1.2× Pacira BioSciences, Inc.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -3.1%, a 4.7% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs -6.7%). Over the past eight quarters, ONE Group Hospitality, Inc.'s revenue compounded faster (56.1% CAGR vs -0.2%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
Target Hospitality is a company that provides workforce lodging and other temporary, modular housing used for oil, gas and mining operations; large-scale events; and disaster relief. Target Hospitality is based in The Woodlands, Texas, and also has offices in Williston, North Dakota; Denver, Colorado; Calgary, Alberta.
PCRX vs STKS — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $177.4M | $207.0M |
| Net Profit | $2.9M | $-6.4M |
| Gross Margin | — | — |
| Operating Margin | 3.9% | 2.2% |
| Net Margin | 1.6% | -3.1% |
| Revenue YoY | 5.0% | -6.7% |
| Net Profit YoY | — | -531.8% |
| EPS (diluted) | $0.07 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | $207.0M | ||
| Q3 25 | $179.5M | $180.2M | ||
| Q2 25 | $181.1M | $207.4M | ||
| Q1 25 | $168.9M | $211.1M | ||
| Q4 24 | $187.3M | $221.9M | ||
| Q3 24 | $168.6M | $194.0M | ||
| Q2 24 | $178.0M | $172.5M |
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | $-6.4M | ||
| Q3 25 | $5.4M | $-76.7M | ||
| Q2 25 | $-4.8M | $-10.1M | ||
| Q1 25 | $4.8M | $975.0K | ||
| Q4 24 | — | $1.5M | ||
| Q3 24 | $-143.5M | $-9.3M | ||
| Q2 24 | $18.9M | $-7.3M |
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | — | ||
| Q3 25 | 80.9% | — | ||
| Q2 25 | 77.4% | — | ||
| Q1 25 | 79.7% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 76.9% | — | ||
| Q2 24 | 75.1% | — |
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | 2.2% | ||
| Q3 25 | 3.5% | -4.4% | ||
| Q2 25 | 4.7% | 0.3% | ||
| Q1 25 | 1.2% | 5.1% | ||
| Q4 24 | 13.2% | 5.5% | ||
| Q3 24 | -82.8% | -1.9% | ||
| Q2 24 | 15.9% | 0.6% |
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | -3.1% | ||
| Q3 25 | 3.0% | -42.6% | ||
| Q2 25 | -2.7% | -4.9% | ||
| Q1 25 | 2.8% | 0.5% | ||
| Q4 24 | — | 0.7% | ||
| Q3 24 | -85.1% | -4.8% | ||
| Q2 24 | 10.6% | -4.3% |
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | $-0.50 | ||
| Q3 25 | $0.12 | $-2.75 | ||
| Q2 25 | $-0.11 | $-0.59 | ||
| Q1 25 | $0.10 | $-0.21 | ||
| Q4 24 | $0.38 | $-0.18 | ||
| Q3 24 | $-3.11 | $-0.53 | ||
| Q2 24 | $0.39 | $-0.38 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.3M | $4.2M |
| Total DebtLower is stronger | — | $354.2M |
| Stockholders' EquityBook value | $653.9M | $-75.8M |
| Total Assets | $1.2B | $884.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | $4.2M | ||
| Q3 25 | $246.3M | $5.5M | ||
| Q2 25 | $445.9M | $4.7M | ||
| Q1 25 | $493.6M | $21.4M | ||
| Q4 24 | $484.6M | $27.6M | ||
| Q3 24 | $453.8M | $28.2M | ||
| Q2 24 | $404.2M | $32.2M |
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | $354.2M | ||
| Q3 25 | $376.7M | $355.0M | ||
| Q2 25 | $580.5M | $347.4M | ||
| Q1 25 | $583.4M | $348.3M | ||
| Q4 24 | $585.3M | $348.3M | ||
| Q3 24 | — | $349.1M | ||
| Q2 24 | — | $350.0M |
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $-75.8M | ||
| Q3 25 | $727.2M | $-61.5M | ||
| Q2 25 | $757.8M | $23.0M | ||
| Q1 25 | $798.5M | $40.5M | ||
| Q4 24 | $778.3M | $45.9M | ||
| Q3 24 | $749.6M | $51.4M | ||
| Q2 24 | $879.3M | $68.1M |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $884.2M | ||
| Q3 25 | $1.3B | $879.5M | ||
| Q2 25 | $1.5B | $935.7M | ||
| Q1 25 | $1.6B | $956.0M | ||
| Q4 24 | $1.6B | $960.1M | ||
| Q3 24 | $1.5B | $953.5M | ||
| Q2 24 | $1.6B | $945.9M |
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | 15.07× | ||
| Q1 25 | 0.73× | 8.61× | ||
| Q4 24 | 0.75× | 7.59× | ||
| Q3 24 | — | 6.79× | ||
| Q2 24 | — | 5.14× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $13.1M |
| Free Cash FlowOCF − Capex | — | $-329.0K |
| FCF MarginFCF / Revenue | — | -0.2% |
| Capex IntensityCapex / Revenue | — | 6.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-27.3M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $43.7M | $13.1M | ||
| Q3 25 | $60.8M | $5.9M | ||
| Q2 25 | $12.0M | $2.8M | ||
| Q1 25 | $35.5M | $8.5M | ||
| Q4 24 | $33.1M | $18.5M | ||
| Q3 24 | $53.9M | $19.1M | ||
| Q2 24 | $53.2M | $-3.8M |
| Q1 26 | — | — | ||
| Q4 25 | $43.5M | $-329.0K | ||
| Q3 25 | $57.0M | $-6.1M | ||
| Q2 25 | $9.3M | $-15.0M | ||
| Q1 25 | $26.9M | $-5.8M | ||
| Q4 24 | $31.0M | $733.0K | ||
| Q3 24 | $49.8M | $287.0K | ||
| Q2 24 | $51.6M | $-23.0M |
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | -0.2% | ||
| Q3 25 | 31.7% | -3.4% | ||
| Q2 25 | 5.1% | -7.2% | ||
| Q1 25 | 15.9% | -2.7% | ||
| Q4 24 | 16.6% | 0.3% | ||
| Q3 24 | 29.6% | 0.1% | ||
| Q2 24 | 29.0% | -13.3% |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 6.5% | ||
| Q3 25 | 2.2% | 6.7% | ||
| Q2 25 | 1.5% | 8.6% | ||
| Q1 25 | 5.1% | 6.8% | ||
| Q4 24 | 1.1% | 8.0% | ||
| Q3 24 | 2.4% | 9.7% | ||
| Q2 24 | 0.9% | 11.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 11.20× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 7.37× | 8.76× | ||
| Q4 24 | — | 12.54× | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.82× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
STKS
| Benihanas | $111.3M | 54% |
| Steakhouse Restaurant | $59.2M | 29% |
| Grill Concepts | $32.3M | 16% |
| Other | $4.2M | 2% |
